Daiichi Sankyo and AstraZeneca have secured a positive recommendation from the Committee for Medicinal Products for Human Use for Enhertu as monotherapy in adult patients with unresectable or metastatic HER2 positive solid tumors who have already received prior treatment and have no satisfactory treatment options. The recommendation places trastuzumab deruxtecan closer to a broader European Union approval that could extend HER2 directed antibody drug conjugate therapy beyond its more established roles in breast, gastric and lung cancer settings.

The strategic importance of the recommendation is not simply that Enhertu may gain another regulatory label. It is that European regulators are moving closer to recognizing HER2 overexpression as a treatment-relevant biomarker across multiple tumor types, not only within traditional organ-specific oncology categories. For clinicians, that could make HER2 testing more relevant in malignancies where it has historically been less routine. For Daiichi Sankyo and AstraZeneca, it strengthens the argument that Enhertu is not just a successful breast cancer and gastric cancer medicine, but a platform asset within precision oncology.

Why could this CHMP opinion matter for patients with HER2 positive metastatic solid tumors?

The clinical gap is clear. HER2 directed therapies have already changed treatment expectations in selected breast and gastric cancers, but many patients with HER2 positive metastatic tumors outside those categories still face limited targeted options after standard therapy. The CHMP recommendation therefore matters because it could create a regulatory pathway for treating HER2 positive disease based on biomarker expression across a broader group of solid tumors.

That shift is clinically meaningful, but it is not automatically simple. A broad solid tumor label depends heavily on the consistency of response across smaller, heterogeneous cohorts. HER2 biology is not identical across biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, lung and colorectal cancers. Tumor microenvironment, prior treatment exposure, disease burden and HER2 expression patterns can all affect outcomes. The recommendation shows regulators saw enough clinical value to support approval, but real-world adoption will depend on how confidently oncologists identify the right patients and how payers interpret the strength of evidence across different cancer types.

The most important practical change may be diagnostic behavior. If Enhertu receives European Commission approval for this broader use, hospitals and oncology networks may have a stronger incentive to test HER2 expression in tumor types where testing has not been routine. That could improve treatment matching, but it also raises workflow questions. Testing capacity, assay standardization, pathology interpretation and turnaround times will matter. A regulatory label can open the door, but diagnostic infrastructure decides how many patients actually walk through it.

How strong is the clinical evidence supporting Enhertu in this broader setting?

The CHMP opinion was supported by data from DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02, which together showed clinically meaningful responses in previously treated patients with HER2 positive tumors. DESTINY-PanTumor02 reported a confirmed objective response rate of 51.4% in patients with HER2 positive solid tumors, while DESTINY-Lung01 showed a confirmed objective response rate of 52.9% in HER2 positive non-small cell lung cancer. DESTINY-CRC02 showed a confirmed objective response rate of 46.9% in HER2 positive colorectal cancer.

Those response rates are notable because they are being observed in patients with advanced disease who had already received prior therapies and had limited remaining options. In that context, objective response rate and duration of response can be highly relevant endpoints, especially when randomized head-to-head data are difficult to generate across rare biomarker-defined subgroups. The data suggest that HER2 overexpression can remain therapeutically actionable across several solid tumors, which is the central logic behind a broader precision oncology label.

However, the evidence base also has limitations that clinicians and health technology assessment bodies will scrutinize. The trials were phase 2 studies, and the patient numbers within specific tumor types were relatively small. DESTINY-Lung01 included 17 HER2 positive patients in the relevant subgroup, while DESTINY-CRC02 included 64 HER2 positive patients. DESTINY-PanTumor02 carried broader weight, but it also included multiple tumor types, which makes interpretation more complex. A strong aggregate response rate may not tell the full story for each individual cancer subtype.

This is where the regulatory and commercial challenge becomes more nuanced. A broad label can be powerful, but clinical confidence often develops tumor by tumor. Oncologists may adopt the therapy more quickly in cancer types where response signals look more durable or where unmet need is especially acute. Other tumor settings may require more post-approval evidence, registry data or additional studies before use becomes routine.

What does Enhertu’s progress reveal about the antibody drug conjugate market?

Enhertu’s broader EU trajectory reinforces how antibody drug conjugates are moving from niche oncology tools into major platform technologies. Antibody drug conjugates combine tumor-targeting antibodies with cytotoxic payloads, aiming to deliver cancer-killing activity more selectively than conventional chemotherapy. Enhertu’s DXd platform has become one of the most closely watched examples because of its activity across HER2 expressing tumors and its expanding clinical development program.

For Daiichi Sankyo and AstraZeneca, the CHMP recommendation adds another layer to a partnership that has already become one of the defining alliances in antibody drug conjugate oncology. Enhertu’s commercial success has given both companies a stronger position in a field where large pharmaceutical groups are aggressively pursuing next-generation payloads, linkers, targets and combination strategies. The broader the clinical utility of Enhertu becomes, the more it validates the idea that antibody drug conjugates can operate as multi-indication franchises rather than single-indication products.

The competitive implications are significant. Oncology companies are now under pressure to show not only that their antibody drug conjugates work in one tumor type, but that their platforms can generate repeatable value across biomarkers and cancer settings. Enhertu’s progress raises the bar for rivals because it combines a recognized target, meaningful clinical response data and an expanding regulatory footprint. Still, the field remains vulnerable to safety, sequencing and resistance challenges. Payload-related toxicity, patient selection and long-term tolerability can determine whether an antibody drug conjugate becomes broadly adopted or remains restricted to narrower populations.

Why HER2 testing could become a bigger issue after a wider Enhertu approval

A broader Enhertu indication would likely push HER2 testing into new clinical conversations across Europe. In breast and gastric cancer, HER2 testing is already embedded in routine treatment pathways. In other solid tumors, it is less consistently performed. That creates an implementation gap between regulatory approval and clinical reach.

The opportunity is straightforward. More routine HER2 testing could identify patients who may otherwise never be considered for a targeted therapy. This fits the wider direction of oncology, where biomarker-based treatment selection is increasingly central to advanced cancer care. If HER2 positive status becomes actionable across a broader group of metastatic solid tumors, testing could become part of a wider molecular profiling strategy rather than a tumor-specific exception.

The risk is that uneven testing practices could create uneven access. Academic cancer centers and large oncology networks may integrate HER2 testing faster than smaller hospitals. Differences in reimbursement for diagnostics, pathology capacity and local treatment guidelines may also affect adoption. A label expansion can broaden eligibility on paper, but without consistent testing pathways, patient access may remain patchy.

There is also a biological challenge. The CHMP recommendation focuses on HER2 positive tumors defined as immunohistochemistry 3+. That is a more clearly positive group than lower-expression categories, but interpretation still depends on reliable pathology. As more tumor types enter the testing conversation, the oncology community may need clearer guidance on assay performance, sample quality and how HER2 expression should be interpreted outside breast and gastric cancer.

What safety questions will clinicians watch as Enhertu moves into wider use?

Enhertu’s safety profile across the supporting trials was described as consistent with previous clinical experience, with no new safety concerns identified. That is important because physicians are already familiar with key adverse event considerations linked to trastuzumab deruxtecan, particularly interstitial lung disease or pneumonitis. In the broader setting, the central question is not whether the safety profile is unknown, but how manageable it remains across more diverse patient populations.

The safety data show why monitoring will remain a major part of real-world use. Interstitial lung disease or pneumonitis occurred across the supporting trials, including fatal events in some datasets. While most events were low grade, the presence of grade 5 cases means clinicians will need to remain vigilant, especially in patients with lung involvement, prior pulmonary compromise or heavy pretreatment histories. For a therapy used in patients with advanced metastatic disease and limited alternatives, the benefit-risk balance may still be favorable, but safety management cannot be treated as a footnote.

This issue becomes more important as Enhertu moves beyond highly specialized centers and into broader clinical practice. Early recognition of pulmonary symptoms, dose modification, treatment interruption and multidisciplinary management will shape outcomes. Real-world data may also reveal whether certain tumor types, prior therapies or patient characteristics influence toxicity risk. Regulators may approve the broader indication, but clinicians will determine how safely and confidently it is used.

How could the European Commission decision affect Daiichi Sankyo and AstraZeneca?

If the European Commission grants marketing authorization, Daiichi Sankyo and AstraZeneca would gain a broader European indication for one of the most commercially and scientifically important antibody drug conjugates in oncology. This would deepen Enhertu’s franchise value and reinforce the companies’ strategy of expanding the medicine across HER2 targetable cancers. It would also strengthen AstraZeneca’s position in oncology, where the company has built a portfolio around targeted therapies, immuno-oncology and antibody drug conjugates.

For Daiichi Sankyo, the decision would further validate its DXd antibody drug conjugate platform, which is central to its oncology identity. Enhertu remains the lead asset, but the broader portfolio includes multiple DXd-based candidates targeting other cancer antigens. A wider Enhertu label could therefore have reputational value beyond this single product, especially as partners, investors and competitors assess which antibody drug conjugate platforms have the strongest clinical and regulatory momentum.

Commercially, the opportunity is meaningful but not unlimited. The addressable population depends on HER2 testing rates, prevalence of IHC 3+ expression across tumor types, physician confidence, reimbursement and treatment sequencing. A broad tumor-agnostic or pan-tumor style label can sound expansive, but the actual patient pool may remain biomarker-defined and relatively selective. The revenue opportunity will likely build gradually as testing expands and clinical guidelines incorporate the indication.

What could still limit adoption even after regulatory approval?

The biggest adoption barrier may be evidence granularity. Regulators can accept a broad dataset showing meaningful activity, but clinicians often want tumor-specific confidence before changing treatment pathways. In rare biomarker-defined settings, that confidence may come through post-approval studies, real-world evidence and accumulated clinical experience. Until then, use may concentrate in tumor types where the unmet need is high and response data are especially persuasive.

Reimbursement could also become a pressure point. Antibody drug conjugates are complex biologic therapies and typically carry high treatment costs. European health technology assessment bodies may examine whether the benefit is consistent across tumor types, whether objective response data are enough to support broad reimbursement, and whether duration of response justifies cost in each setting. A European Commission approval would be a major step, but country-level access decisions may still determine how quickly patients receive treatment.

Treatment sequencing is another unresolved question. Patients with advanced solid tumors often receive multiple lines of therapy, including chemotherapy, immunotherapy, targeted therapy and trial-based options. Enhertu’s place in the sequence may vary by tumor type, biomarker profile and local standard of care. In some cancers, it may become a preferred later-line option for HER2 positive disease. In others, clinicians may reserve it for highly selected patients until more evidence emerges.

Why this recommendation could mark a broader shift in precision oncology strategy

The Enhertu CHMP recommendation is part of a larger shift toward treating cancer through actionable biology rather than only tissue origin. That does not mean tumor location is becoming irrelevant. Far from it. Tumor type still shapes prognosis, treatment sequence, resistance patterns and clinical trial design. However, the ability of a HER2 directed antibody drug conjugate to show activity across multiple solid tumors supports the argument that certain biomarkers can create cross-tumor therapeutic opportunities.

The more important long-term effect may be cultural. If oncologists increasingly view HER2 overexpression as worth testing across metastatic solid tumors, precision oncology becomes less confined to a few well-established molecular categories. That could benefit patients with less common tumors or heavily pretreated cancers where standard options are limited. It could also encourage more drug developers to design trials around biomarker-defined cohorts spanning several cancer types.

The caution is that precision oncology is only as strong as its evidence and implementation. Broad biomarker strategies can fail if response rates are inconsistent, diagnostics are uneven or toxicity limits practical use. Enhertu’s data are strong enough to support a positive CHMP opinion, but the next phase will depend on how the medicine performs across routine clinical settings, how guidelines incorporate it and how regulators and payers manage the balance between innovation and evidence certainty.

What should clinicians and industry observers watch next?

The immediate next step is the European Commission review. A formal approval would make Enhertu available for a wider group of adult patients with previously treated HER2 positive metastatic solid tumors in the European Union, subject to the final label and national access decisions. Clinicians will watch whether the final indication closely follows the CHMP recommendation and how quickly treatment guidelines respond.

Beyond approval, the real test will be adoption. HER2 testing rates in non-traditional tumor types, country-level reimbursement decisions, real-world safety monitoring and tumor-specific outcome data will determine whether this becomes a meaningful practice shift or a more selective niche expansion. The response rates from DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02 provide a strong regulatory foundation, but the commercial and clinical story will now move into the slower, messier territory of implementation.

For Daiichi Sankyo and AstraZeneca, the recommendation strengthens Enhertu’s position as one of the leading antibody drug conjugates in global oncology. For the broader industry, it offers another signal that the next phase of cancer drug development will be shaped by platform medicines, biomarker expansion and regulatory willingness to consider cross-tumor evidence when unmet need remains high. The opportunity is real, but so is the burden of proving that precision oncology can scale beyond specialist centers and into everyday cancer care.

  antibody drug conjugates, AstraZeneca, CHMP, Daiichi Sankyo, DESTINY-CRC02, DESTINY-Lung01, DESTINY-PanTumor02, Enhertu, European Medicines Agency, HER2 positive solid tumors, trastuzumab deruxtecan